Tuesday, May 21, 2024
HomeWellnessDrugs and MedicationsIngrezza Is the First Drug Approved By the FDA to Treat Tardive...

Ingrezza Is the First Drug Approved By the FDA to Treat Tardive Dyskinesia

FDA approves the novel drug Ingrezza, which targets the vesicular monoamine transporter 2 implicated in dopamine release and motor control

 

Dyskinesia is a disorder that causes the uncontrollable or involuntary movement of the body. Tardive dyskinesia (TD) is a rare and difficult-to-treat neurological disorder characterized by the involuntary movement of the face and jaw. Patients with this disorder primarily display repetitive facial movements like grimacing, smacking their lips, and sticking out their tongue. In some cases, patients may also experience involuntary movement of their extremities or swaying of their trunk.

TD occurs most frequently in patients who have a long history of taking antipsychotic medications prescribed for schizophrenia, depression or bipolar disorder, and can further stigmatize patients suffering from mental illness. Decreasing the dose of these medications may help relieve symptoms, but there is currently no cure for TD.

The FDA has recently approved the first drug to treat TD, Ingrezza (valbenazine). A drug developed by Neurocrine Biosciences Inc., Ingrezza capsules selectively inhibit vesicular monoamine transporter 2, a protein that regulates the release of dopamine. Dopamine signals to brain regions that control movement, and Ingrezza works by reducing the amount of dopamine released to these motor control regions.

Ingrezza has received FDA approval due to its success in numerous clinical trials. In a Phase 3 trial of 234 adult participants with underlying mental illness, those receiving Ingrezza once a day showed significant improvement after six weeks in the severity of their involuntary movements compared to those who had received placebo. It was overall well tolerated by participants and there was no observable worsening of depression, suicidal ideation or other related behaviours.

The approval of Ingrezza is a key milestone in the treatment of TD and will hopefully help patients manage the often persistent and irreversible side effects of long-term antipsychotic use.

 

Written By: Fiona Wong, PhD

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

Recognizing HIE: A Call for Advocacy

Have you heard of HIE? It’s the second leading cause of infant mortality and lifelong disability worldwide. 2-3 per 1,000 live births in high-income...

Joke Of The Day – May 21

Recently in the news,  it was announced that The New England Medical Journal reports:  9 out of 10 doctors agree that 1 out of...

ADVERTISE WITH US

error: Content is read-only and copy-protected.